Avid Bioservices (CDMO) Tops Q3 EPS by 2c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts CDMO Hot Sheet
Join SI Premium – FREE
Avid Bioservices (NASDAQ: CDMO) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $38 million versus the consensus estimate of $36.32 million.
GUIDANCE:
Avid Bioservices sees FY2023 revenue of $145-150 million, versus the consensus of $146 million.
For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
